Alkermes reports Q2 2026 revenue $496.0M, GAAP net income $0.5M, Adjusted EBITDA $139.2M
I'm LongbridgeAI, I can summarize articles.Alkermes reported Q2 2026 revenue of $496.0M and Adjusted EBITDA of $139.2M, driven by strong product sales including LYBALVI and ARISTADAi. The company reaffirmed full-year guidance while updating net loss and EBITDA forecasts due to a ~$25M increase in contingent consideration from the Avadel acquisition. Additionally, Blair Jackson is set to become CEO on August 1, 2026, succeeding Richard Pops.
Alkermes reported second-quarter 2026 total revenues of $496.0 million, GAAP net income of $0.5 million and Adjusted EBITDA of $139.2 million. The company reaffirmed full-year revenue and product sales ranges while updating GAAP net loss and EBITDA guidance to reflect a ~$25 million increase in contingent consideration tied to the Avadel acquisition. Leadership transition announced: Blair Jackson will become CEO on August 1, 2026, with Richard Pops remaining as chairman.
Financial Highlights
- Total revenues for Q2 2026: $496.0 million (Q2 2025: $390.7 million).
- Total proprietary net sales for Q2 2026: $411.7 million (Q2 2025: $307.2 million).
- GAAP net income (loss): Q2 2026 net income $0.5 million; six months ended June 30, 2026 net loss $(66.0) million.
- Adjusted EBITDA: Q2 2026 $139.2 million; six months ended June 30, 2026 $219.5 million.
- Cash, cash equivalents and total investments at June 30, 2026: $691.6 million (March 31, 2026: $538.2 million).
Business Highlights
- Product performance: LYBALVI net sales $94.0 million with prescriptions up 18% year-over-year; ARISTADAi $96.7 million; VIVITROL $124.5 million; LUMRYZ $96.6 million (includes ~$7 million inventory timing benefit).
- Manufacturing & royalties: VUMERITY manufacturing and royalty revenues $30.6 million; royalty revenues from XEPLION/INVEGA TRINZA/TREVICTA and related brands $27.5 million; RISPERDAL CONSTA manufacturing revenue $20.9 million.
- Acquisition integration: Results include the Feb. 12, 2026 Avadel acquisition — inventory step-up and related costs recorded; company recorded $26.4 million increase in fair value of contingent consideration tied to a LUMRYZ phase 3 milestone.
- Pipeline and clinical progress: Orexin 2 receptor agonist portfolio advancing — first ADHD data for ALKS 7290 expected in coming months and topline alixorexton Phase 2 idiopathic hypersomnia results expected toward year-end.
- Leadership and strategic focus: Blair Jackson to assume CEO role Aug. 1, 2026; management emphasizes execution on commercial momentum and growth opportunities in sleep medicine and neuroscience.
Original SEC Filing: Alkermes plc. [ ALKS ] - 8-K - Jul. 28, 2026